Injectable hydrogels as matrix to retain microparticles for controlled delivery of anti-VEGF proteins for ocular applications
Wet age-related macular degeneration (AMD) or diabetic macular edema (DME) are potentially retinal diseases and they are treated by monthly or bimonthly intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as aflibercept (Eylea®) and ranibizumab (Lucentis®). Because...
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | |
| 格式: | Final Year Project |
| 語言: | English |
| 出版: |
2017
|
| 主題: | |
| 在線閱讀: | http://hdl.handle.net/10356/70120 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|